The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE
Phase 2
Recruiting
- Conditions
- Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
- Registration Number
- JPRN-jRCT2071220084
- Lead Sponsor
- Ishii Kyoko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Are SCLE, DLE and/or SLE participants that have completed the 24-week Treatment of the WILLOW study.
Exclusion Criteria
Participants who experienced serious event(s) related to the study intervention during the WILLOW study, an unstable medical condition, or any other reason, in the opinion of the Investigator or Sponsor/designee that would preclude participation in this LTE study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of adverse events (TEAEs, SAEs, and AESIs) from Day 1 through the end of the Safety Follow-up period (up to Week 50)
- Secondary Outcome Measures
Name Time Method